UY34271A - Anticuerpos anti-tie2 y usos de los mismos - Google Patents

Anticuerpos anti-tie2 y usos de los mismos

Info

Publication number
UY34271A
UY34271A UY0001034271A UY34271A UY34271A UY 34271 A UY34271 A UY 34271A UY 0001034271 A UY0001034271 A UY 0001034271A UY 34271 A UY34271 A UY 34271A UY 34271 A UY34271 A UY 34271A
Authority
UY
Uruguay
Prior art keywords
same
tie2 antibodies
tie2
antibodies
escanear
Prior art date
Application number
UY0001034271A
Other languages
English (en)
Inventor
Thurston Gavin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY34271A publication Critical patent/UY34271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona anticuerpos que se unen a Tie2 y métodos de uso de los mismos. Según ciertas realizaciones de la invención, los anticuerpos son anticuerpos completamente humanos que se unen a Tie2 humano y bloquean la interacción 5 entre Tie2 y uno o más ligandos de Tie2, tales como angiopoyetina 1 (Ang1), angiopoyetina 2 (Ang2), angiopoyetina 3 (Ang3) y/o angiopoyetina 4 (Ang4). Los anticuerpos de la invención son útiles, entre otros, para el tratamiento de enfermedades y trastornos asociados a una o más actividades biológicas de Tie2, que incluyen la angiogénesis.
UY0001034271A 2011-08-19 2012-08-17 Anticuerpos anti-tie2 y usos de los mismos UY34271A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525308P 2011-08-19 2011-08-19
US201261587213P 2012-01-17 2012-01-17
US201261674405P 2012-07-23 2012-07-23

Publications (1)

Publication Number Publication Date
UY34271A true UY34271A (es) 2013-02-28

Family

ID=46785799

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034271A UY34271A (es) 2011-08-19 2012-08-17 Anticuerpos anti-tie2 y usos de los mismos

Country Status (15)

Country Link
US (4) US9017670B2 (es)
EP (2) EP3415533A1 (es)
JP (2) JP6333174B2 (es)
KR (1) KR20140054303A (es)
CN (2) CN106963946A (es)
AR (1) AR087567A1 (es)
AU (1) AU2012299195B9 (es)
CA (1) CA2844306C (es)
ES (1) ES2694411T3 (es)
IL (1) IL230529A (es)
IN (1) IN2014CN02025A (es)
MX (1) MX359833B (es)
SG (1) SG10201606872TA (es)
UY (1) UY34271A (es)
WO (1) WO2013028442A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
KR20140054303A (ko) 2011-08-19 2014-05-08 리제너론 파아마슈티컬스, 인크. 항-Ｔｉｅ２ 항체 및 이의 용도
CN105873599A (zh) * 2013-11-01 2016-08-17 瑞泽恩制药公司 用于治疗脑型疟疾的基于血管生成素的干预手段
WO2016010014A1 (ja) * 2014-07-15 2016-01-21 アステラス製薬株式会社 新規抗ヒトＴｉｅ２抗体
WO2016115092A1 (en) * 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
WO2018148567A1 (en) 2017-02-09 2018-08-16 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting immunotherapy intervention
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
CA3101506A1 (en) * 2018-06-07 2019-12-12 Institute For Basic Science Anti-tie2 antibodies and use thereof
WO2019235856A1 (ko) * 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
CN112638401A (zh) 2018-06-29 2021-04-09 璟尚生物制药公司 抗肿瘤拮抗剂
CN114340735A (zh) 2019-06-28 2022-04-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
EP3960763A4 (en) * 2019-08-14 2022-12-28 Pharmabcine Inc. ANTI-TIE 2 ANTIBODIES AND ITS USE
AU2020385991A1 (en) * 2019-11-21 2022-06-23 Unity Biotechnology Antibodies directed to Tie-2 and methods of use
JP2023519213A (ja) 2020-03-24 2023-05-10 ジェネンテック， インコーポレイテッド Ｔｉｅ２結合剤および使用方法
WO2022225182A1 (ko) * 2021-04-23 2022-10-27 (주)니오테스바이오 안지오포이에틴-2에 특이적으로 결합하는 항체, 또는 이의 단편
US20240279324A1 (en) 2021-06-03 2024-08-22 Gensun Biopharma Inc. Multispecific antagonists
WO2023137395A1 (en) * 2022-01-13 2023-07-20 Ingenia Therapeutics Inc. Vegf and tie2-binding fusion protein and uses thereof
CN115947818B (zh) * 2022-10-25 2024-08-02 福州大学 一种血管生成素1突变体的设计及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1994000469A1 (en) 1992-06-26 1994-01-06 Immunex Corporation Novel tyrosine kinase
US5681714A (en) 1992-07-30 1997-10-28 Mount Sinai Hospital Corporation Nucleic acid encoding tek receptor tyrosine kinase
WO1995013387A1 (en) 1993-11-12 1995-05-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tie-2, a novel receptor tyrosine kinase
AUPM379494A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
US20030040463A1 (en) * 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US6365154B1 (en) 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
NZ516258A (en) 1999-06-07 2004-02-27 Immunex Corp Tek antagonists
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CA2394015C (en) * 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor
BR0111861A (pt) 2000-06-23 2003-12-23 Schering Ag Combinações e composições que interferem com função receptora vegf/vegf e angiopoietina/tie e seu uso(ii)
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
EP1761281A1 (en) * 2004-06-04 2007-03-14 Pfizer Products Incorporated Method for treating abnormal cell growth
WO2006005361A1 (en) * 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
CA2576886A1 (en) 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
US7745641B2 (en) 2005-04-19 2010-06-29 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
CA2693383C (en) 2006-10-27 2017-03-28 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US8685393B2 (en) * 2008-03-24 2014-04-01 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of systemic anthrax infection
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20130188013A1 (en) * 2011-07-22 2013-07-25 Qualcomm Incorporated Mvc based 3dvc codec supporting inside view motion prediction (ivmp) mode
KR20140054303A (ko) 2011-08-19 2014-05-08 리제너론 파아마슈티컬스, 인크. 항-Ｔｉｅ２ 항체 및 이의 용도

Also Published As

Publication number Publication date
MX359833B (es) 2018-10-12
US20180291105A1 (en) 2018-10-11
KR20140054303A (ko) 2014-05-08
CN103874709B (zh) 2016-12-21
AU2012299195B9 (en) 2018-05-10
IN2014CN02025A (es) 2015-05-29
ES2694411T3 (es) 2018-12-20
EP2744827A1 (en) 2014-06-25
US10442864B2 (en) 2019-10-15
NZ621481A (en) 2016-04-29
AU2012299195A1 (en) 2014-03-13
IL230529A0 (en) 2014-03-31
US9017670B2 (en) 2015-04-28
US20170088622A1 (en) 2017-03-30
JP6333174B2 (ja) 2018-05-30
US10023641B2 (en) 2018-07-17
WO2013028442A1 (en) 2013-02-28
JP2017186347A (ja) 2017-10-12
JP2014525934A (ja) 2014-10-02
JP6654165B2 (ja) 2020-02-26
US9546218B2 (en) 2017-01-17
EP2744827B1 (en) 2018-10-03
MX2014001738A (es) 2014-03-27
CN103874709A (zh) 2014-06-18
CA2844306A1 (en) 2013-02-28
US20150197578A1 (en) 2015-07-16
IL230529A (en) 2017-07-31
CN106963946A (zh) 2017-07-21
SG10201606872TA (en) 2016-10-28
AR087567A1 (es) 2014-04-03
EP3415533A1 (en) 2018-12-19
US20130209492A1 (en) 2013-08-15
AU2012299195B2 (en) 2018-04-19
CA2844306C (en) 2022-08-16

Similar Documents

Publication Publication Date Title
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
TWD180147S (zh) 淨水器
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
ECSP14005975A (es) Anticuerpos anti-PHF-tau y sus usos
UY34539A (es) Heteroarilos y usos de los mismos
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
UY34018A (es) Derivados glucósidos y usos de los mismos
UY33946A (es) Derivados de c4-monometil triterpenoides y sus métodos de uso
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
UY34502A (es) Arilos y heteroarilos bicíclicos inhibidores de los canales de sodio
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
CO6940376A2 (es) Anticuerpos anti-psgl-1 y usos de los mismos
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN